Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey

par Schandelmaier, Stefan, Schmitt, Andreas M, Herbrand, Amanda K, Glinz, Dominik, Ewald, Hannah, Briel, Matthias, Guyatt, Gordon H, Hemkens, Lars G, Kasenda, Benjamin
Publié dans BMJ Open (2020)

Predicting protein targets for drug-like compounds using transcriptomics

par Pabon, Nicolas A., Xia, Yan, Estabrooks, Samuel K., Ye, Zhaofeng, Herbrand, Amanda K., Süß, Evelyn, Biondi, Ricardo M., Assimon, Victoria A., Gestwicki, Jason E., Brodsky, Jeffrey L., Camacho, Carlos J., Bar-Joseph, Ziv
Publié dans PLoS Comput Biol (2018)

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

par Ladanie, Aviv, Schmitt, Andreas M., Speich, Benjamin, Naudet, Florian, Agarwal, Arnav, Pereira, Tiago V., Sclafani, Francesco, Herbrand, Amanda K., Briel, Matthias, Martin-Liberal, Juan, Schmid, Thomas, Ewald, Hannah, Ioannidis, John P. A., Bucher, Heiner C., Kasenda, Benjamin, Hemkens, Lars G.
Publié dans JAMA Netw Open (2020)

Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)—rationale and design for an international collaborative study

par Kasenda, Benjamin, Liu, Junhao, Jiang, Yu, Gajewski, Byron, Wu, Cen, von Elm, Erik, Schandelmaier, Stefan, Moffa, Giusi, Trelle, Sven, Schmitt, Andreas Michael, Herbrand, Amanda K., Gloy, Viktoria, Speich, Benjamin, Hopewell, Sally, Hemkens, Lars G., Sluka, Constantin, McGill, Kris, Meade, Maureen, Cook, Deborah, Lamontagne, Francois, Tréluyer, Jean-Marc, Haidich, Anna-Bettina, Ioannidis, John P. A., Treweek, Shaun, Briel, Matthias
Publié dans Trials (2020)